Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia

Joanne N. Luke, Alex Brown, David N. O'Neal, Kerin O'Dea, Alicia J. Jenkins, Margaret Kelaher, James D. Best, Kevin G. Rowley

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To evaluate the extent to which the current Pharmaceutical Benefits Scheme (PBS) guidelines for patient eligibility for lipid-lowering medication are applicable to Aboriginal people in Central Australia. Design, setting and participants: A 10-year cohort study of 659 Aboriginal people who participated in population-based cardiovascular disease (CVD) risk factor surveys in 1995 and who were free of CVD at baseline, for the period from 1995 to 2004-2005 or until first CVD event. Evidence of atherosclerotic CVD (ischaemic heart disease, ischaemic stroke, and peripheral vascular disease) was sought from hospital, primary health care and death records. PBS eligibility was assigned according to the current PBS criteria, which were amended in 2006 to include Aboriginal-specific criteria, using participants' baseline (1995) and 10-year follow-up data. Main outcome measures: Proportions of PBS-eligible and PBS-ineligible participants who had CVD events during the study period; sensitivity and specificity of the criteria. Results: Of 42 participants who had CVD events during the study period, 35 were PBS-eligible (incidence, 1130/100 000 person-years; relative risk compared with PBS-ineligible population, 4.87 [95% CI, 2.19-10.80]) and seven were PBS-ineligible. PBS eligibility was associated with older mean age (37 v 32 years) and male sex (48% v 37%), with 50.7% of participants (334/659) meeting eligibility criteria. The mean high-density lipoprotein cholesterol level at baseline was very low in both groups (0.81 v 0.87mmol/L). The current PBS guidelines have low specificity (52%) in this population, which was found to improve (to 71%-82%) by incorporating additional non-lipid criteria (age and multiple non-lipid risk factors). Conclusion: The current PBS lipid treatment criteria, which include any Aboriginal person with diabetes and less stringent cholesterol thresholds than the previous version, identify a group at very high risk of CVD. Global risk assessment may better identify those at risk.

LanguageEnglish
Pages552-556
Number of pages5
JournalMedical Journal of Australia
Volume190
Issue number10
Publication statusPublished - 18 May 2009
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Luke, J. N., Brown, A., O'Neal, D. N., O'Dea, K., Jenkins, A. J., Kelaher, M., ... Rowley, K. G. (2009). Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Medical Journal of Australia, 190(10), 552-556.
Luke, Joanne N. ; Brown, Alex ; O'Neal, David N. ; O'Dea, Kerin ; Jenkins, Alicia J. ; Kelaher, Margaret ; Best, James D. ; Rowley, Kevin G. / Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. In: Medical Journal of Australia. 2009 ; Vol. 190, No. 10. pp. 552-556.
@article{dd0bc15532cb4aeba40e062fa44bea8f,
title = "Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia",
abstract = "Objective: To evaluate the extent to which the current Pharmaceutical Benefits Scheme (PBS) guidelines for patient eligibility for lipid-lowering medication are applicable to Aboriginal people in Central Australia. Design, setting and participants: A 10-year cohort study of 659 Aboriginal people who participated in population-based cardiovascular disease (CVD) risk factor surveys in 1995 and who were free of CVD at baseline, for the period from 1995 to 2004-2005 or until first CVD event. Evidence of atherosclerotic CVD (ischaemic heart disease, ischaemic stroke, and peripheral vascular disease) was sought from hospital, primary health care and death records. PBS eligibility was assigned according to the current PBS criteria, which were amended in 2006 to include Aboriginal-specific criteria, using participants' baseline (1995) and 10-year follow-up data. Main outcome measures: Proportions of PBS-eligible and PBS-ineligible participants who had CVD events during the study period; sensitivity and specificity of the criteria. Results: Of 42 participants who had CVD events during the study period, 35 were PBS-eligible (incidence, 1130/100 000 person-years; relative risk compared with PBS-ineligible population, 4.87 [95{\%} CI, 2.19-10.80]) and seven were PBS-ineligible. PBS eligibility was associated with older mean age (37 v 32 years) and male sex (48{\%} v 37{\%}), with 50.7{\%} of participants (334/659) meeting eligibility criteria. The mean high-density lipoprotein cholesterol level at baseline was very low in both groups (0.81 v 0.87mmol/L). The current PBS guidelines have low specificity (52{\%}) in this population, which was found to improve (to 71{\%}-82{\%}) by incorporating additional non-lipid criteria (age and multiple non-lipid risk factors). Conclusion: The current PBS lipid treatment criteria, which include any Aboriginal person with diabetes and less stringent cholesterol thresholds than the previous version, identify a group at very high risk of CVD. Global risk assessment may better identify those at risk.",
author = "Luke, {Joanne N.} and Alex Brown and O'Neal, {David N.} and Kerin O'Dea and Jenkins, {Alicia J.} and Margaret Kelaher and Best, {James D.} and Rowley, {Kevin G.}",
year = "2009",
month = "5",
day = "18",
language = "English",
volume = "190",
pages = "552--556",
journal = "The Medical journal of Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "10",

}

Luke, JN, Brown, A, O'Neal, DN, O'Dea, K, Jenkins, AJ, Kelaher, M, Best, JD & Rowley, KG 2009, 'Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia', Medical Journal of Australia, vol. 190, no. 10, pp. 552-556.

Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. / Luke, Joanne N.; Brown, Alex; O'Neal, David N.; O'Dea, Kerin; Jenkins, Alicia J.; Kelaher, Margaret; Best, James D.; Rowley, Kevin G.

In: Medical Journal of Australia, Vol. 190, No. 10, 18.05.2009, p. 552-556.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia

AU - Luke, Joanne N.

AU - Brown, Alex

AU - O'Neal, David N.

AU - O'Dea, Kerin

AU - Jenkins, Alicia J.

AU - Kelaher, Margaret

AU - Best, James D.

AU - Rowley, Kevin G.

PY - 2009/5/18

Y1 - 2009/5/18

N2 - Objective: To evaluate the extent to which the current Pharmaceutical Benefits Scheme (PBS) guidelines for patient eligibility for lipid-lowering medication are applicable to Aboriginal people in Central Australia. Design, setting and participants: A 10-year cohort study of 659 Aboriginal people who participated in population-based cardiovascular disease (CVD) risk factor surveys in 1995 and who were free of CVD at baseline, for the period from 1995 to 2004-2005 or until first CVD event. Evidence of atherosclerotic CVD (ischaemic heart disease, ischaemic stroke, and peripheral vascular disease) was sought from hospital, primary health care and death records. PBS eligibility was assigned according to the current PBS criteria, which were amended in 2006 to include Aboriginal-specific criteria, using participants' baseline (1995) and 10-year follow-up data. Main outcome measures: Proportions of PBS-eligible and PBS-ineligible participants who had CVD events during the study period; sensitivity and specificity of the criteria. Results: Of 42 participants who had CVD events during the study period, 35 were PBS-eligible (incidence, 1130/100 000 person-years; relative risk compared with PBS-ineligible population, 4.87 [95% CI, 2.19-10.80]) and seven were PBS-ineligible. PBS eligibility was associated with older mean age (37 v 32 years) and male sex (48% v 37%), with 50.7% of participants (334/659) meeting eligibility criteria. The mean high-density lipoprotein cholesterol level at baseline was very low in both groups (0.81 v 0.87mmol/L). The current PBS guidelines have low specificity (52%) in this population, which was found to improve (to 71%-82%) by incorporating additional non-lipid criteria (age and multiple non-lipid risk factors). Conclusion: The current PBS lipid treatment criteria, which include any Aboriginal person with diabetes and less stringent cholesterol thresholds than the previous version, identify a group at very high risk of CVD. Global risk assessment may better identify those at risk.

AB - Objective: To evaluate the extent to which the current Pharmaceutical Benefits Scheme (PBS) guidelines for patient eligibility for lipid-lowering medication are applicable to Aboriginal people in Central Australia. Design, setting and participants: A 10-year cohort study of 659 Aboriginal people who participated in population-based cardiovascular disease (CVD) risk factor surveys in 1995 and who were free of CVD at baseline, for the period from 1995 to 2004-2005 or until first CVD event. Evidence of atherosclerotic CVD (ischaemic heart disease, ischaemic stroke, and peripheral vascular disease) was sought from hospital, primary health care and death records. PBS eligibility was assigned according to the current PBS criteria, which were amended in 2006 to include Aboriginal-specific criteria, using participants' baseline (1995) and 10-year follow-up data. Main outcome measures: Proportions of PBS-eligible and PBS-ineligible participants who had CVD events during the study period; sensitivity and specificity of the criteria. Results: Of 42 participants who had CVD events during the study period, 35 were PBS-eligible (incidence, 1130/100 000 person-years; relative risk compared with PBS-ineligible population, 4.87 [95% CI, 2.19-10.80]) and seven were PBS-ineligible. PBS eligibility was associated with older mean age (37 v 32 years) and male sex (48% v 37%), with 50.7% of participants (334/659) meeting eligibility criteria. The mean high-density lipoprotein cholesterol level at baseline was very low in both groups (0.81 v 0.87mmol/L). The current PBS guidelines have low specificity (52%) in this population, which was found to improve (to 71%-82%) by incorporating additional non-lipid criteria (age and multiple non-lipid risk factors). Conclusion: The current PBS lipid treatment criteria, which include any Aboriginal person with diabetes and less stringent cholesterol thresholds than the previous version, identify a group at very high risk of CVD. Global risk assessment may better identify those at risk.

UR - http://www.scopus.com/inward/record.url?scp=68149136307&partnerID=8YFLogxK

M3 - Article

VL - 190

SP - 552

EP - 556

JO - The Medical journal of Australia

T2 - The Medical journal of Australia

JF - The Medical journal of Australia

SN - 0025-729X

IS - 10

ER -

Luke JN, Brown A, O'Neal DN, O'Dea K, Jenkins AJ, Kelaher M et al. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Medical Journal of Australia. 2009 May 18;190(10):552-556.